Summary
The prevalence of chronic HBV and HCV infection varies widely between European countries. Cost-effectiveness analyses may need to take effect of antiviral treatment on preventing HBV and HCV transmission.
Main navigation
-
Data
Open related submenu
Data
Explore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.
Latest datasets
-
Countries
Open related submenu
Countries
We work closely with the 27 EU Member States plus Norway and Türkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.
-
Topics
Open related submenu
Selected topics
-
Best practice
Open related submenu
Best practice
The content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses.
In this section
-
Publications
Open related submenu
Publications
Explore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it.
In this section
Featured publications
- Events Open related submenu
-
News
Open related submenu
-
About
Open related submenu
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the leading authority on illicit drugs in the European Union.
In this section